Indian Rabies Vaccine Under Scrutiny: Understanding Treatment and Regulatory Challenges
Indian rabies vaccine faces scrutiny over counterfeits; understanding treatment and regulatory gaps is crucial.
Photo by CDC
Background Context
Why It Matters Now
Key Takeaways
- •Rabies is nearly 100% fatal once symptoms appear, making post-exposure vaccination critical.
- •The controversy involved genuine vaccine product being diverted to the open market through packaging changes, not outright counterfeiting.
- •India accounts for a significant portion of global rabies deaths.
- •Robust drug regulation and supply chain integrity are essential to prevent such incidents and maintain public trust.
- •Proper wound washing and timely immunoglobulin administration are crucial alongside vaccination.
Different Perspectives
- •The article presents the manufacturer's clarification and expert opinion on treatment. A broader perspective might include the economic impact on India's pharmaceutical exports or the role of international agencies in monitoring drug quality.
India's rabies vaccine, Abhayrab, manufactured by Indian Immunologicals, is under international scrutiny after concerns about potentially counterfeit batches circulating since 2023. This alarm was raised by health departments in Australia, the UK, and the US, highlighting a critical public health issue, as rabies is nearly 100% fatal once symptoms develop.
While Indian Immunologicals identified one specific batch with different packaging, tests confirmed the genuine product inside, suggesting diversion of government supply to the open market rather than outright counterfeiting. The incident underscores the vulnerabilities in India's drug supply chain and the urgent need for robust regulatory oversight to ensure vaccine efficacy and prevent vaccine hesitancy, especially given India accounts for 36% of global rabies deaths.
Key Facts
Concerns raised over counterfeit batches of Indian rabies vaccine 'Abhayrab'
Manufactured by Human Biologicals Institute (Indian Immunologicals)
Advisories issued by Australia, UK, US health departments
One specific batch (#KA24014) identified with different packaging
Tests confirmed genuine product inside, suggesting diversion of supply
India accounts for nearly 36% of global rabies deaths
WHO vaccination schedule: at least 3 intramuscular or 2 intradermal doses plus immunoglobulin for animal bites
UPSC Exam Angles
Public Health and Disease Control (Rabies, Vaccine Efficacy)
Drug Regulation and Governance (CDSCO, Drugs & Cosmetics Act, Supply Chain Management)
Pharmaceutical Industry and Global Trade (India's role as a drug manufacturer, international reputation)
Social Issues (Vaccine Hesitancy, Access to Healthcare, Public Trust)
Ethical Dimensions (Drug diversion, patient safety)
Visual Insights
Global Rabies Burden & International Scrutiny on Indian Vaccine (2023-2025)
This map highlights India's significant contribution to global rabies deaths and the countries that raised concerns about the Indian-manufactured rabies vaccine, Abhayrab, since 2023. It underscores the international dimension of drug supply chain vulnerabilities.
Loading interactive map...
Key Statistics: Rabies & Vaccine Scrutiny in India (2023-2025)
This dashboard presents critical statistics related to rabies fatality and India's global burden, along with the timeline of the vaccine scrutiny, emphasizing the urgency of the public health issue.
- India's Share of Global Rabies Deaths
- 36%Stable (high)
- Rabies Fatality Rate (Once Symptoms Develop)
- Nearly 100%N/A
- Start of International Scrutiny on Abhayrab
- 2023N/A
Highlights India's disproportionately high burden of rabies, making effective vaccine supply critical.
Emphasizes the critical importance of timely and effective post-exposure prophylaxis (PEP) and reliable vaccines.
Marks the beginning of concerns raised by international health departments, leading to the current public health issue.
Practice Questions (MCQs)
1. Consider the following statements regarding Rabies and its prevention in India: 1. Rabies is a viral zoonotic disease that primarily affects the central nervous system and is almost 100% fatal once symptoms develop. 2. India's National Rabies Control Programme (NRCP) primarily focuses on pre-exposure prophylaxis (PrEP) for the general population. 3. Post-exposure prophylaxis (PEP) for rabies typically involves wound washing, administration of rabies immunoglobulin (RIG), and a series of rabies vaccine doses. Which of the statements given above is/are correct?
- A.1 only
- B.1 and 3 only
- C.2 and 3 only
- D.1, 2 and 3
Show Answer
Answer: B
Statement 1 is correct. Rabies is indeed a viral zoonotic disease affecting the CNS and is nearly 100% fatal once symptoms appear. Statement 2 is incorrect. While PrEP exists for high-risk groups, NRCP's primary focus is on post-exposure prophylaxis (PEP) and animal bite management, along with mass dog vaccination to control the disease reservoir. PrEP for the general population is not the primary focus. Statement 3 is correct. PEP for rabies involves immediate wound washing, administration of rabies immunoglobulin (RIG) if indicated, and a full course of rabies vaccine doses.
2. In the context of drug regulation and supply chain management in India, consider the following statements: 1. The Central Drugs Standard Control Organisation (CDSCO) is responsible for the approval of new drugs and clinical trials, and also for licensing of drug manufacturing units. 2. State Drug Regulatory Authorities are primarily responsible for licensing of manufacturing establishments and sales premises, and for monitoring the quality of drugs manufactured and sold within their respective states. 3. The Drugs and Cosmetics Act, 1940, and Rules thereunder, provide the legal framework for drug regulation in India, covering aspects from manufacturing to sale and distribution. Which of the statements given above is/are correct?
- A.1 and 2 only
- B.2 and 3 only
- C.1 and 3 only
- D.1, 2 and 3
Show Answer
Answer: B
Statement 1 is incorrect. CDSCO is responsible for approval of new drugs, clinical trials, and setting standards. However, the licensing of drug manufacturing units (and sales premises) is primarily handled by the State Drug Regulatory Authorities, not CDSCO directly, though CDSCO plays a role in coordination and specific categories of licenses. Statement 2 is correct. State Drug Regulatory Authorities are indeed responsible for licensing manufacturing and sales premises and for quality control within their states. Statement 3 is correct. The Drugs and Cosmetics Act, 1940, and its subsequent rules, form the foundational legal framework for drug regulation in India.
3. Which of the following statements best explains the term 'vaccine hesitancy' in the context of public health?
- A.The refusal to vaccinate due to religious beliefs.
- B.Delay in acceptance or refusal of vaccination despite availability of vaccination services.
- C.The inability to access vaccines due to supply chain disruptions.
- D.A medical condition that prevents an individual from receiving certain vaccines.
Show Answer
Answer: B
Option A is too narrow; while religious beliefs can contribute, vaccine hesitancy is broader. Option C describes a supply-side issue, not hesitancy. Option D describes a contraindication, not hesitancy. Option B accurately defines vaccine hesitancy as a spectrum of behaviors, ranging from delay in acceptance to outright refusal, despite the availability of vaccines. This includes concerns about safety, efficacy, necessity, or trust in the healthcare system.
4. Consider the following statements regarding India's pharmaceutical sector and its global standing: 1. India is often referred to as the 'pharmacy of the world' due to its significant contribution to the global supply of generic medicines and vaccines. 2. The 'Make in India' initiative has primarily focused on promoting the export of Active Pharmaceutical Ingredients (APIs) rather than finished formulations. 3. Incidents of drug diversion or quality concerns can significantly impact India's reputation and trust in its pharmaceutical exports globally. Which of the statements given above is/are correct?
- A.1 only
- B.1 and 2 only
- C.1 and 3 only
- D.2 and 3 only
Show Answer
Answer: C
Statement 1 is correct. India is indeed known as the 'pharmacy of the world' due to its large-scale production and export of affordable generic drugs and vaccines. Statement 2 is incorrect. While 'Make in India' aims to boost domestic manufacturing across sectors, including pharmaceuticals, it focuses on both APIs (to reduce import dependence) and finished formulations, not primarily one over the other. India has historically been strong in finished formulations but is now pushing for API self-reliance. Statement 3 is correct. Any concerns regarding quality, counterfeiting, or diversion directly undermine trust in the Indian pharmaceutical industry, potentially affecting its export markets and global standing.
Related Articles
NCERT Textbook Revisions Spark Controversy: Key Changes and Concerns
High Court halts 'Kerala Story 2' release, asks CBFC review
Kerala Inaugurates Ayurveda Research Institute, Seeks Global Recognition
Telangana Government Plans Elaborate Iftar Dinner Events in Hyderabad
Women's Stories from Northeast India: Conflict, Resilience, and Identity